Julisia Chau

The efficient identification and elimination of cancer cells without harm to normal tissues remains a challenge in cancer therapy. Our lab recently developed the concept of Rewiring Aberrant Signaling to Effector Release (RASER), in which an oncogenic protein activity, rather than being suppressed, is detected and rewired to a therapeutic output. My research focuses on improving and fundamentally expanding RASER. My goal is to increase the contrast of RASER such that system responses to strong ErbB signaling are enhanced while background activity is reduced. I am also designing a new RASER system to detect other classes of oncogenic mutations.